Northland Capmk Weighs in on Cardio Diagnostics Holdings, Inc.’s Q2 2023 Earnings (NASDAQ:CDIO)

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Rating) – Analysts at Northland Capmk issued their Q2 2023 earnings per share estimates for shares of Cardio Diagnostics in a research report issued on Monday, May 22nd. Northland Capmk analyst C. Byrnes expects that the company will earn ($0.21) per share for the quarter. Northland Capmk also issued estimates for Cardio Diagnostics’ Q3 2023 earnings at ($0.21) EPS, Q4 2023 earnings at ($0.21) EPS, FY2023 earnings at ($0.75) EPS, FY2024 earnings at ($0.75) EPS, FY2025 earnings at ($0.70) EPS and FY2026 earnings at ($0.55) EPS.

Separately, Northland Securities initiated coverage on shares of Cardio Diagnostics in a research note on Monday. They issued an “outperform” rating for the company.

Cardio Diagnostics Price Performance

Shares of Cardio Diagnostics stock opened at $1.38 on Wednesday. The business has a 50-day simple moving average of $2.81 and a 200-day simple moving average of $2.23. Cardio Diagnostics has a one year low of $0.80 and a one year high of $10.25.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CDIO. Bank of America Corp DE acquired a new stake in Cardio Diagnostics during the 1st quarter worth $59,000. Susquehanna International Group LLP acquired a new stake in shares of Cardio Diagnostics in the fourth quarter valued at approximately $26,000. State Street Corp purchased a new position in shares of Cardio Diagnostics during the first quarter worth approximately $163,000. Finally, Geode Capital Management LLC acquired a new position in shares of Cardio Diagnostics in the 1st quarter valued at $290,000. Hedge funds and other institutional investors own 77.29% of the company’s stock.

About Cardio Diagnostics

(Get Rating)

Cardio Diagnostics Holdings, Inc, a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.